Comparison of Vical Incorporated (VICL) and SELLAS Life Sciences Group Inc. (NASDAQ:SLS)

This is therefore a contrasting of the institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation in Vical Incorporated (NASDAQ:VICL) and SELLAS Life Sciences Group Inc. (NASDAQ:SLS). The two are both Biotechnology companies that compete with one another.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vical Incorporated 1 105.19 N/A -0.55 0.00
SELLAS Life Sciences Group Inc. 1 0.00 N/A -2.63 0.00

Table 1 highlights Vical Incorporated and SELLAS Life Sciences Group Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 shows us Vical Incorporated and SELLAS Life Sciences Group Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Vical Incorporated 0.00% -26% -24.6%
SELLAS Life Sciences Group Inc. 0.00% -600.2% -141.8%

Risk and Volatility

A 0.27 beta indicates that Vical Incorporated is 73.00% less volatile compared to S&P 500. SELLAS Life Sciences Group Inc.’s 30.00% more volatile than S&P 500 which is a result of the 1.3 beta.

Liquidity

The Current Ratio and a Quick Ratio of Vical Incorporated are 36.8 and 36.8. Competitively, SELLAS Life Sciences Group Inc. has 0.6 and 0.6 for Current and Quick Ratio. Vical Incorporated’s better ability to pay short and long-term obligations than SELLAS Life Sciences Group Inc.

Analyst Ratings

Vical Incorporated and SELLAS Life Sciences Group Inc. Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Vical Incorporated 0 0 0 0.00
SELLAS Life Sciences Group Inc. 0 0 1 3.00

Competitively the consensus price target of SELLAS Life Sciences Group Inc. is $4.5, which is potential 2,716.02% upside.

Insider & Institutional Ownership

Vical Incorporated and SELLAS Life Sciences Group Inc. has shares owned by institutional investors as follows: 33.9% and 11.8%. Vical Incorporated’s share owned by insiders are 0.97%. Insiders Comparatively, owned 2.04% of SELLAS Life Sciences Group Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Vical Incorporated 4.75% -15.31% -40.14% -27.32% -48.01% -39.64%
SELLAS Life Sciences Group Inc. 34.6% 47.83% -82.42% -88.36% -84.82% -86.18%

For the past year Vical Incorporated has stronger performance than SELLAS Life Sciences Group Inc.

Summary

Vical Incorporated beats SELLAS Life Sciences Group Inc. on 7 of the 8 factors.

Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It is developing various DNA-based vaccines and other therapeutics, such as VCL-HB01 therapeutic vaccine for herpes simplex virus-2 that is in Phase II clinical trial to prevent and protect against lesion recurrence; VL-2397 antifungal program, which is in Phase I clinical trial for the treatment of invasive fungal infections; and CyMVectin prophylactic vaccine for CMV that is in preclinical stage for the prevention of fetal transmission during pregnancy. The company also engages in contract manufacturing of plasmid investigational products for various clients. It has collaborations with Astellas to develop and commercialize certain products, including ASP0113 for the control and prevention of CMV infection in immunocompromised patients; and Merial for use of the companyÂ’s core DNA delivery technology in a therapeutic vaccine designed to aid in extending survival time of dogs with oral melanoma. It also has a license agreement with Astellas to develop and commercialize novel antifungal candidate. The company was founded in 1987 and is headquartered in San Diego, California.

SELLAS Life Sciences Group, Inc., a development-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S, a cancer immunotherapeutic agent for the treatment of hematologic cancers and solid tumor indications, including acute myeloid leukemia, malignant pleural mesothelioma, multiple myeloma, ovarian cancer, immune combo, and chronic myelogenous leukemia. It also develops NEUVAX, which is in Phase II clinical trial for the treatment of breast cancer; and Anagrelide controlled release, which has completed various clinical trials for the treatment of thrombocythemia. The company has collaboration and license agreements with Memorial Sloan Kettering Cancer Center, Advaxis Immunotherapies, Merck & Co., Inc., National Cancer Institute, and the University of Texas M.D. Anderson Cancer Center. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.